AK129 Combination Therapy for Advanced Solid Tumors

This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.

Trial Details

NCT ID
NCT06943820
Phase
PHASE1 / PHASE2
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • AK129(dose 1)
  • Pemetrexed
  • Paclitaxel
  • Carboplatin
  • AK129(dose 2)
  • Docetaxel
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);
  • ≥18 years old and ≤ 75 years (regardless of sex);
  • ECOG performance status 0-1;
  • Life expectancy longer than 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →